Nuwellis, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 11, 2024. Although the request references 2023 Q4, this is an annual report covering the full fiscal year, not a standalone quarterly report.
Business context
Nuwellis develops, manufactures and commercializes the Aquadex ultrafiltration systems, used to remove excess fluid from patients whose fluid overload has not responded to medical management, including diuretics. Its primary markets are critical care, heart failure and pediatrics. The Aquadex SmartFlow system is cleared for adults and pediatric patients weighing at least 20 kg. Nuwellis had one reportable operating segment and no other commercial product at year-end.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $8.864 million | $8.543 million |
| Gross profit / margin | $4.983 million / 56.2% | $4.755 million / 55.7% |
| Operating loss | $(17.630) million | $(17.171) million |
| Net loss | $(20.209) million | $(14.525) million |
| Net loss attributable to common stockholders | $(22.627) million | $(14.525) million |
| Net loss per share, basic and diluted | $(11.52) | $(83.55) |
| Cash used in operating activities | $17.937 million | $15.149 million |
| Cash and marketable securities at year-end | $3.800 million | $18.306 million |
Revenue increased 3.8%, attributed mainly to higher circuit, service-related and international sales, partly offset by lower console sales. Gross margin improved modestly, but operating expenses rose to $22.613 million as R&D increased 24.9% to $5.422 million, primarily for the pediatric kidney-replacement device. SG&A declined 2.2% to $17.191 million. The company recorded an $800,000 non-recurring incentive-compensation expense reduction and $550,000 of SeaStar-related SG&A expense.
The net loss widened despite the improvement in gross profit. Results included $3.483 million of financing expense and $758,000 of income from the change in fair value of warrant liabilities; the prior year included $9.247 million of financing expense and $11.827 million of warrant fair-value income. The 2023 common-stockholder loss also reflects $2.297 million of deemed dividends and $121,000 of Series J preferred-stock dividends. These items affect comparability with operating performance.
At December 31, 2023, current assets were $8.209 million and current liabilities were $3.172 million. Total liabilities were $6.559 million, including a $2.843 million common-stock warrant liability and $760,000 of operating lease liabilities; the filing does not report conventional funded debt. Stockholders’ equity was $2.990 million. The company had an accumulated deficit of $287.6 million.
Material changes, outlook and risks
- Funding and going concern: Management says existing capital resources are expected to support the operating plan only through May 31, 2024, and additional funding is needed. The filing and auditor’s report state that recurring losses, negative operating cash flows and the need for working capital raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months from the report date. No assurance is given that new financing will be available.
- Cost reduction: Nuwellis reported actions intended to reduce monthly cash burn by approximately 40%, including selected job eliminations, salary and board-fee reductions, suspension of the 401(k) match, travel cuts and reductions in professional-services spending.
- Financing and dilution: The October 2023 Series J preferred-stock and warrant offering generated $2.25 million gross and approximately $1.5 million net proceeds. Warrant valuation resulted in a $2.7 million day-one financing expense. At year-end, 2.963 million common-stock warrants and preferred securities convertible into common stock were outstanding; further equity financing could dilute shareholders. The filing reports 5.682 million common shares outstanding at December 31, 2023, and 6.801 million at March 1, 2024.
- Nasdaq listing: Nasdaq notified the company in December 2023 that its share price had been below $1 for 30 consecutive trading days. The stated compliance deadline was June 4, 2024; failure to regain compliance could lead to delisting, subject to potential additional time and other requirements.
- Clinical and product development: REVERSE-HF had 91 patients enrolled as of February 10, 2024; management targeted 372 patients and expected full enrollment by mid-2025, with primary-endpoint analysis and publication hoped for in the second half of 2025. The Vivian pediatric CRRT device completed preliminary engineering testing in Q4 2023; the company planned an IDE submission in Q3 2024 and anticipated U.S. commercialization in Q4 2025. These are plans, not assured outcomes.
- Other developments: SeaStar received FDA HDE approval for its pediatric product on February 22, 2024, after year-end; Nuwellis recorded a $450,000 milestone liability. A DaVita pilot for Aquadex inpatient and outpatient services was underway, with an option for DaVita to extend the agreement for up to 10 years. The filing gives no assurance that the option will be exercised or that the pilot will produce material revenue.
- Control and operating risks: Management concluded that disclosure controls and internal control over financial reporting were ineffective at year-end, citing material weaknesses related to staffing and segregation of duties, and insufficient contemporaneous control documentation. Other notable risks include dependence on Aquadex and a concentrated customer base (the largest customer generated 13.9% of FY2023 revenue), uncertain reimbursement, supplier dependence, and potential product, regulatory and international compliance issues. German VAT returns for 2017–2021 were overdue; the company said it could not yet calculate potential interest or penalties.
Most important facts for investors to verify
- Whether Nuwellis obtained sufficient financing after the filing to extend its stated cash runway and address the going-concern uncertainty.
- Subsequent cash burn, revenue trends, customer concentration and progress toward the targeted 40% monthly cash-burn reduction.
- Nasdaq bid-price compliance and any reverse-split, extension or delisting developments.
- REVERSE-HF enrollment and timeline, Vivian regulatory milestones, and evidence that DaVita or SeaStar arrangements generate commercial sales.
- Progress in remediating the disclosed material weaknesses and any subsequent changes to reported controls or financial statements.
- The Series J preferred-stock, warrant and other potential share issuance terms and their effect on dilution; also reconcile the warrant-liability amounts, which differ between the balance sheet and the Note 6 fair-value roll-forward.